{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:12:56Z","timestamp":1793747576574,"version":"4.6.1"},"reference-count":140,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":252,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","award":["2021YFS0221"],"award-info":[{"award-number":["2021YFS0221"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","award":["2023YFS0179"],"award-info":[{"award-number":["2023YFS0179"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["2022HXFH032"],"award-info":[{"award-number":["2022HXFH032"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["ZYJC21058"],"award-info":[{"award-number":["ZYJC21058"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["2021-023"],"award-info":[{"award-number":["2021-023"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["2022-014"],"award-info":[{"award-number":["2022-014"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>Corneal diseases represent 5.1% of all eye defects and are the fourth leading cause of blindness globally. Corneal neovascularization can arise from all conditions of chronic irritation or hypoxia, which disrupts the immune\u2010privileged state of the healthy cornea, increases the risk of rejection after keratoplasty, and leads to opacity. In the past decades, significant progress has been made for neovascular diseases of the retina and choroid, with plenty of drugs getting commercialized. In addition, to overcome the barriers of the short duration and inadequate penetration of conventional formulations of antivascular endothelial growth factor (VEGF), multiple novel drug delivery systems, including adeno\u2010associated virus (AAV)\u2010mediated transfer have gone through the full process of bench\u2010to\u2010bedside translation. Like retina neovascular diseases, corneal neovascularization also suffers from chronicity and a high risk of recurrence, necessitating sustained and efficient delivery across the epithelial barrier to reach deep layers of the corneal stroma. Among the explored methods, adeno\u2010associated virus\u2010mediated delivery of anti\u2010VEGF to treat corneal neovascularization is the most extensively researched and most promising strategy for clinical translation although currently although, it remains predominantly at the preclinical stage. This review comprehensively examines the necessity, benefits, and risks of applying AAV vectors for anti\u2010VEGF drug delivery in corneal vascularization, including its current progress and challenges in clinical translation.<\/jats:p>","DOI":"10.1155\/2024\/5487973","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T15:19:26Z","timestamp":1725895166000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sustained and Efficient Delivery of Antivascular Endothelial Growth Factor by the Adeno\u2010associated Virus for the Treatment of Corneal Neovascularization: An Outlook for Its Clinical Translation"],"prefix":"10.1155","volume":"2024","author":[{"given":"Mengzhen","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-5313","authenticated-orcid":false,"given":"Lixiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5193-428X","authenticated-orcid":false,"given":"Ke","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingye","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0720-8616","authenticated-orcid":false,"given":"Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"e_1_2_13_1_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.preteyeres.2010.01.002","article-title":"Novel aspects of corneal angiogenic and lymphangiogenic privilege","volume":"29","author":"Ellenberg D.","year":"2010","journal-title":"Progress in Retinal and Eye Research"},{"key":"e_1_2_13_2_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2021.108502","article-title":"The cornea IV immunology, infection, neovascularization, and surgery chapter 1: corneal immunology","volume":"205","author":"Mousa H. M.","year":"2021","journal-title":"Experimental Eye Research"},{"key":"e_1_2_13_3_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4103\/0301-4738.100540","article-title":"Turning the tide of corneal blindness","volume":"60","author":"Oliva M. S.","year":"2012","journal-title":"Indian Journal of Ophthalmology"},{"key":"e_1_2_13_4_2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/bjophthalmol-2011-300539","article-title":"Global estimates of visual impairment: 2010","volume":"96","author":"Pascolini D.","year":"2012","journal-title":"British Journal of Ophthalmology"},{"key":"e_1_2_13_5_2","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1097\/ICL.0000000000000412","article-title":"Critical contact lens oxygen transmissibility and tear lens oxygen tension to preclude corneal neovascularization","volume":"44","author":"Yeung K. K.","year":"2018","journal-title":"Eye and Contact Lens: Science and Clinical Practice"},{"key":"e_1_2_13_6_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108363","article-title":"Corneal neovascularization","volume":"202","author":"Nicholas M. P.","year":"2021","journal-title":"Experimental Eye Research"},{"key":"e_1_2_13_7_2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ophtha.2011.01.041","article-title":"Horizons in therapy for corneal angiogenesis","volume":"118","author":"Maddula S.","year":"2011","journal-title":"Ophthalmology"},{"key":"e_1_2_13_8_2","first-page":"264","article-title":"Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis)","volume":"104","author":"Azar D. T.","year":"2006","journal-title":"Transactions of the American Ophthalmological Society"},{"key":"e_1_2_13_9_2","first-page":"253","article-title":"Targeting VEGF in eye neovascularization: What\u2019s new?: a comprehensive review on current therapies and oligonucleotide-based interventions under development","volume":"103","author":"Amadio M.","year":"2016","journal-title":"Pharmacological Research"},{"key":"e_1_2_13_10_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/17425247.2016.1227783","article-title":"Recent perspectives on the delivery of biologics to back of the eye","volume":"14","author":"Joseph M.","year":"2017","journal-title":"Expert Opinion on Drug Delivery"},{"key":"e_1_2_13_11_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.preteyeres.2015.06.002","article-title":"Molecular pathogenesis of retinal and choroidal vascular diseases","volume":"49","author":"Campochiaro P. A.","year":"2015","journal-title":"Progress in Retinal and Eye Research"},{"key":"e_1_2_13_12_2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s13346-022-01231-5","article-title":"Ocular barriers as a double-edged sword: preventing and facilitating drug delivery to the retina","volume":"13","author":"Wang L.","year":"2023","journal-title":"Drug Delivery and Translational Research"},{"key":"e_1_2_13_13_2","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.7150\/thno.78426","article-title":"Small extracellular vesicle-loaded bevacizumab reduces the frequency of intravitreal injection required for diabetic retinopathy","volume":"13","author":"Reddy S. K.","year":"2023","journal-title":"Theranostics"},{"key":"e_1_2_13_14_2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40123-021-00365-y","article-title":"The emerging role of topical ocular drugs to target the posterior eye","volume":"10","author":"Wang L.","year":"2021","journal-title":"Ophthalmology and Therapy"},{"key":"e_1_2_13_15_2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jtos.2018.06.004","article-title":"Current and emerging therapies for corneal neovascularization","volume":"16","author":"Roshandel D.","year":"2018","journal-title":"Ocular Surface"},{"key":"e_1_2_13_16_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.survophthal.2017.10.006","article-title":"Gene-based antiangiogenic applications for corneal neovascularization","volume":"63","author":"Liu S.","year":"2018","journal-title":"Survey of Ophthalmology"},{"key":"e_1_2_13_17_2","doi-asserted-by":"crossref","DOI":"10.1186\/s40942-021-00343-3","article-title":"Future of anti-VEGF: biosimilars and biobetters","volume":"8","author":"Kapur M.","year":"2022","journal-title":"International Journal of Retina and Vitreous"},{"key":"e_1_2_13_18_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/ICU.0000000000000849","article-title":"Brolucizumab for the treatment of diabetic macular edema","volume":"33","author":"Kuo B. L.","year":"2022","journal-title":"Current Opinion in Ophthalmology"},{"key":"e_1_2_13_19_2","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.696201","article-title":"Conbercept for treatment of neovascular age-related macular degeneration and visual impairment due to diabetic macular edema or pathologic myopia choroidal neovascularization: a systematic review and meta-analysis","volume":"12","author":"Zhou P.","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"e_1_2_13_20_2","first-page":"185","article-title":"Observation of total VEGF level in hyperglycemic mouse eyes after intravitreal injection of the novel anti-VEGF drug conbercept","volume":"21","author":"Du L.","year":"2015","journal-title":"Molecular Vision"},{"key":"e_1_2_13_21_2","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s00417-013-2392-6","article-title":"Anti-angiogenic effect of KH902 on retinal neovascularization","volume":"251","author":"Wang F.","year":"2013","journal-title":"Graefes Archive for Clinical and Experimental Ophthalmology"},{"key":"e_1_2_13_22_2","first-page":"2311","article-title":"Profile of conbercept in the treatment of neovascular age-related macular degeneration","volume":"9","author":"Lu X.","year":"2015","journal-title":"Drug Design, Development and Therapy"},{"key":"e_1_2_13_23_2","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.723","article-title":"Biological drug therapy for ocular angiogenesis: anti-VEGF agents and novel strategies based on nanotechnology","volume":"9","author":"Formica M. L.","year":"2021","journal-title":"Pharmacology Research & Perspectives"},{"key":"e_1_2_13_24_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.sjopt.2017.02.008","article-title":"Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization","volume":"31","author":"Al-Debasi T.","year":"2017","journal-title":"Saudi Journal of Ophthalmology"},{"key":"e_1_2_13_25_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization","volume":"127","author":"Mohammad H.","year":"2009","journal-title":"Archives of Ophthalmology"},{"key":"e_1_2_13_26_2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/ICO.0b013e31823f8d71","article-title":"Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study","volume":"31","author":"Benayoun Y.","year":"2012","journal-title":"Cornea"},{"key":"e_1_2_13_27_2","doi-asserted-by":"crossref","first-page":"7376","DOI":"10.1167\/iovs.14-15257","article-title":"Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization","volume":"55","author":"Kim Y. C.","year":"2014","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_13_28_2","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/ICO.0b013e3181d92834","article-title":"Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty","volume":"29","author":"Foroutan A.","year":"2010","journal-title":"Cornea"},{"key":"e_1_2_13_29_2","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e3182775f8d","article-title":"Topical ranibizumab as a treatment of corneal neovascularization","volume":"32","author":"Ferrari G.","year":"2013","journal-title":"Cornea"},{"key":"e_1_2_13_30_2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54171-5","article-title":"Optical coherence tomography angiography imaging to monitor anti-VEGF treatment of corneal vascularization in a rabbit model","volume":"9","author":"Devarajan K.","year":"2019","journal-title":"Scientific Reports"},{"key":"e_1_2_13_31_2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000356407","article-title":"High-dose topical bevacizumab for corneal neovascularization","volume":"92","author":"Waisbourd M.","year":"2013","journal-title":"Pharmacology"},{"key":"e_1_2_13_32_2","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ophtha.2022.03.024","article-title":"Bevacizumab in high-risk corneal transplantation: a pilot multicenter prospective randomized control trial","volume":"129","author":"Dohlman T. H.","year":"2022","journal-title":"Ophthalmology"},{"key":"e_1_2_13_33_2","doi-asserted-by":"crossref","DOI":"10.1177\/09603271221084674","article-title":"The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization","volume":"41","author":"Eski M. T.","year":"2022","journal-title":"Human & Experimental Toxicology"},{"key":"e_1_2_13_34_2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/15569527.2020.1760877","article-title":"Comparison of the effect of topical bevacizumab and sorafenib in experimental corneal neovascularization","volume":"39","author":"Yildirim H.","year":"2020","journal-title":"Cutaneous and Ocular Toxicology"},{"key":"e_1_2_13_35_2","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1159\/000510114","article-title":"Resolution of refractory corneal neovascularization with subconjunctival bevacizumab","volume":"11","author":"Britton A. K.","year":"2020","journal-title":"Case Reports in Ophthalmology"},{"key":"e_1_2_13_36_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00417-019-04519-4","article-title":"Intrastromal bevacizumab in the management of corneal neovascularization: a retrospective review","volume":"258","author":"Gupta A. A.","year":"2020","journal-title":"Graefes Archive for Clinical and Experimental Ophthalmology"},{"key":"e_1_2_13_37_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/bjophthalmol-2012-302137","article-title":"Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial","volume":"97","author":"Petsoglou C.","year":"2013","journal-title":"British Journal of Ophthalmology"},{"key":"e_1_2_13_38_2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/ICL.0000000000000709","article-title":"Subconjunctival aflibercept for the treatment of formed corneal neovascularization","volume":"47","author":"Sella R.","year":"2021","journal-title":"Eye and Contact Lens: Science and Clinical Practice"},{"key":"e_1_2_13_39_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00417-013-2495-0","article-title":"Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes","volume":"252","author":"Moisseiev E.","year":"2014","journal-title":"Graefes Archive for Clinical and Experimental Ophthalmology"},{"key":"e_1_2_13_40_2","doi-asserted-by":"crossref","first-page":"8718","DOI":"10.1167\/iovs.11-7871","article-title":"Corneal penetration of topical and subconjunctival bevacizumab","volume":"52","author":"Dastjerdi M. H.","year":"2011","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_13_41_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jtos.2018.10.002","article-title":"Pathogenesis of herpes simplex keratitis: the host cell response and ocular surface sequelae to infection and inflammation","volume":"17","author":"Lobo A. M.","year":"2019","journal-title":"Ocular Surface"},{"key":"e_1_2_13_42_2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.preteyeres.2005.04.001","article-title":"Gene therapy in the cornea","volume":"24","author":"Mohan R. R.","year":"2005","journal-title":"Progress in Retinal and Eye Research"},{"key":"e_1_2_13_43_2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jtos.2012.10.004","article-title":"Corneal gene therapy: basic science and translational perspective","volume":"11","author":"Mohan R. R.","year":"2013","journal-title":"Ocular Surface"},{"key":"e_1_2_13_44_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.preteyeres.2011.09.001","article-title":"Gene therapy in the cornea: 2005--present","volume":"31","author":"Mohan R. R.","year":"2012","journal-title":"Progress in Retinal and Eye Research"},{"key":"e_1_2_13_45_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1089\/jop.2022.0022","article-title":"Retinal and choroidal neovascularization antivascular endothelial growth factor treatments: the role of gene therapy","volume":"38","author":"Toutounchian S.","year":"2022","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"key":"e_1_2_13_46_2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/1566523221666210423084233","article-title":"Gene therapy in the anterior eye segment","volume":"22","author":"Amador C.","year":"2022","journal-title":"Current Gene Therapy"},{"key":"e_1_2_13_47_2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1089\/hum.2015.025","article-title":"Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success--a personal perspective","volume":"26","author":"Hastie E.","year":"2015","journal-title":"Human Gene Therapy"},{"key":"e_1_2_13_48_2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang D.","year":"2019","journal-title":"Nature Reviews Drug Discovery"},{"key":"e_1_2_13_49_2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/sj.cgt.7700876","article-title":"Adeno-associated virus vectors: potential applications for cancer gene therapy","volume":"12","author":"Li C.","year":"2005","journal-title":"Cancer Gene Therapy"},{"key":"e_1_2_13_50_2","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12080767","article-title":"Adeno-associated virus mediated gene therapy for corneal diseases","volume":"12","author":"Bastola P.","year":"2020","journal-title":"Pharmaceutics"},{"key":"e_1_2_13_51_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi K. J.","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_13_52_2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/hum.2019.367","article-title":"Postmortem analysis in a clinical trial of AAV2-NGF gene therapy for Alzheimer\u2019s disease identifies a need for improved vector delivery","volume":"31","author":"Castle M. J.","year":"2020","journal-title":"Human Gene Therapy"},{"key":"e_1_2_13_53_2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","article-title":"Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial","volume":"388","author":"Bennett J.","year":"2016","journal-title":"Lancet (London, England)"},{"key":"e_1_2_13_54_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/humc.2017.146","article-title":"Safety of intradiaphragmatic delivery of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by pompe disease","volume":"28","author":"Corti M.","year":"2017","journal-title":"Hum Gene Ther Clin Dev"},{"key":"e_1_2_13_55_2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41434-020-0171-7","article-title":"Investigation of the safety and feasibility of AAV1\/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD TRIAL","volume":"27","author":"Lyon A. R.","year":"2020","journal-title":"Gene Therapy"},{"key":"e_1_2_13_56_2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1073\/pnas.1617726114","article-title":"Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for \u03b1-1-antitrypsin deficiency","volume":"114","author":"Calcedo R.","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"e_1_2_13_57_2","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","article-title":"Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial","volume":"6","author":"Priddy F. H.","year":"2019","journal-title":"Lancet HIV"},{"key":"e_1_2_13_58_2","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MDNA3-0052-2014","article-title":"Adeno-associated virus as a mammalian DNA vector","volume":"3","author":"Salganik M.","year":"2015","journal-title":"Microbiology Spectrum"},{"key":"e_1_2_13_59_2","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar C. E.","year":"2018","journal-title":"Science"},{"key":"e_1_2_13_60_2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1146\/annurev-virology-092818-015530","article-title":"Recombinant adeno-associated virus gene therapy in light of Luxturna (and Zolgensma and Glybera): where are we, and how did we get here?","volume":"6","author":"Keeler A. M.","year":"2019","journal-title":"Annual review of virology"},{"key":"e_1_2_13_61_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102394","article-title":"Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study","volume":"67","author":"Khanani A. M.","year":"2024","journal-title":"EClinicalMedicine"},{"key":"e_1_2_13_62_2","first-page":"2344","article-title":"Subconjunctival injection of recombinant AAV-angiostatin ameliorates alkali burn induced corneal angiogenesis","volume":"13","author":"Cheng H.-C.","year":"2007","journal-title":"Molecular Vision"},{"key":"e_1_2_13_63_2","first-page":"151","article-title":"State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications","volume":"18","author":"Wang D.","year":"2014","journal-title":"Discovery Medicine"},{"key":"e_1_2_13_64_2","first-page":"67","article-title":"State-of-the-art human gene therapy: part I. Gene delivery technologies","volume":"18","author":"Wang D.","year":"2014","journal-title":"Discovery Medicine"},{"key":"e_1_2_13_65_2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.brainresbull.2009.07.005","article-title":"Transduction efficiency of AAV 2\/6, 2\/8 and 2\/9 vectors for delivering genes in human corneal fibroblasts","volume":"81","author":"Sharma A.","year":"2010","journal-title":"Brain Research Bulletin"},{"key":"e_1_2_13_66_2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.exer.2010.06.020","article-title":"AAV serotype influences gene transfer in corneal stroma in vivo","volume":"91","author":"Sharma A.","year":"2010","journal-title":"Experimental Eye Research"},{"key":"e_1_2_13_67_2","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.10.10.5","article-title":"Six-month in vivo safety profiling of topical ocular AAV5-decorin gene transfer","volume":"10","author":"Mohan R. R.","year":"2021","journal-title":"Translational Vision Science & Technology"},{"key":"e_1_2_13_68_2","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1073\/pnas.1821000116","article-title":"AAV cis-regulatory sequences are correlated with ocular toxicity","volume":"116","author":"Xiong W.","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the U S A"},{"key":"e_1_2_13_69_2","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12040335","article-title":"Controlled release of rAAV vectors from APMA-functionalized contact lenses for corneal gene therapy","volume":"12","author":"Alvarez-Rivera F.","year":"2020","journal-title":"Pharmaceutics"},{"key":"e_1_2_13_70_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11373-007-9153-7","article-title":"Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model","volume":"14","author":"Lai L.-J.","year":"2007","journal-title":"Journal of Biomedical Science"},{"key":"e_1_2_13_71_2","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.ymthe.2022.06.018","article-title":"Corneal fibrosis abrogation by a localized AAV-mediated inhibitor of differentiation 3 (Id3) gene therapy in rabbit eyes in vivo","volume":"30","author":"Gupta S.","year":"2022","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"e_1_2_13_72_2","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1167\/iovs.11-7357","article-title":"Significant inhibition of corneal scarring in vivo with tissue-selective, targeted AAV5 decorin gene therapy","volume":"52","author":"Mohan R. R.","year":"2011","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_13_73_2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/ICO.0000000000002182","article-title":"A fixed-depth microneedle enhances reproducibility and safety for corneal gene therapy","volume":"39","author":"Gilger B. C.","year":"2020","journal-title":"Cornea"},{"key":"e_1_2_13_74_2","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1089\/hum.2019.071","article-title":"Gene delivery to human limbal stem cells using viral vectors","volume":"30","author":"Song L.","year":"2019","journal-title":"Human Gene Therapy"},{"key":"e_1_2_13_75_2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41434-018-0035-6","article-title":"Serotype survey of AAV gene delivery via subconjunctival injection in mice","volume":"25","author":"Song L.","year":"2018","journal-title":"Gene Therapy"},{"key":"e_1_2_13_76_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035318","article-title":"Corneal transduction by intra-stromal injection of AAV vectors in vivo in the mouse and ex vivo in human explants","volume":"7","author":"Hippert C.","year":"2012","journal-title":"PLoS One"},{"key":"e_1_2_13_77_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/978-1-4939-9139-6_15","article-title":"Intracameral delivery of AAV to corneal endothelium for expression of secretory proteins","volume":"1950","author":"O\u2032Callaghan J.","year":"2019","journal-title":"Methods in Molecular Biology"},{"key":"e_1_2_13_78_2","doi-asserted-by":"crossref","DOI":"10.1038\/srep22131","article-title":"AAV gene therapy for MPS1-associated corneal blindness","volume":"6","author":"Vance M.","year":"2016","journal-title":"Scientific Reports"},{"key":"e_1_2_13_79_2","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao G.-P.","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"e_1_2_13_80_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.omtm.2021.06.007","article-title":"Efficacious, safe, and stable inhibition of corneal neovascularization by AAV-vectored anti-VEGF therapeutics","volume":"22","author":"Su W.","year":"2021","journal-title":"Molecular Therapy Methods & Clinical Development"},{"key":"e_1_2_13_81_2","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/hmg\/ddx028","article-title":"Therapeutic potential of AAV-mediated MMP-3 secretion from corneal endothelium in treating glaucoma","volume":"26","author":"O\u2032Callaghan J.","year":"2017","journal-title":"Human Molecular Genetics"},{"key":"e_1_2_13_82_2","doi-asserted-by":"crossref","DOI":"10.1038\/srep22131","article-title":"AAV gene therapy for MPS1-associated corneal blindness","volume":"6","author":"Vance M.","year":"2016","journal-title":"Scientific Reports"},{"key":"e_1_2_13_83_2","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ymthe.2020.04.004","article-title":"Intrastromal gene therapy prevents and reverses advanced corneal clouding in a canine model of Mucopolysaccharidosis I","volume":"28","author":"Miyadera K.","year":"2020","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"e_1_2_13_84_2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li C.","year":"2020","journal-title":"Nature Reviews Genetics"},{"key":"e_1_2_13_85_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026432","article-title":"Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivo","volume":"6","author":"Mohan R. R.","year":"2011","journal-title":"PLoS One"},{"key":"e_1_2_13_86_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018771","article-title":"Efficacious and safe tissue-selective controlled gene therapy approaches for the cornea","volume":"6","author":"Mohan R. R.","year":"2011","journal-title":"PLoS One"},{"key":"e_1_2_13_87_2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1089\/hum.2015.167","article-title":"Efficient transduction of corneal stroma by adeno-associated viral serotype vectors for implications in gene therapy of corneal diseases","volume":"27","author":"Lu Y.","year":"2016","journal-title":"Human Gene Therapy"},{"key":"e_1_2_13_88_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128759","article-title":"Capsid mutated adeno-associated virus delivered to the anterior chamber results in efficient transduction of trabecular meshwork in mouse and rat","volume":"10","author":"Bogner B.","year":"2015","journal-title":"PLoS One"},{"key":"e_1_2_13_89_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1167\/iovs.09-3847","article-title":"Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys","volume":"51","author":"Buie L. K.","year":"2010","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_13_90_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182473","article-title":"Single stranded adeno-associated virus achieves efficient gene transfer to anterior segment in the mouse eye","volume":"12","author":"Wang L.","year":"2017","journal-title":"PLoS One"},{"key":"e_1_2_13_91_2","first-page":"1389","article-title":"Inhibition of mouse alkali burn induced-corneal neovascularization by recombinant adenovirus encoding human vasohibin-1","volume":"16","author":"Zhou S.-Y.","year":"2010","journal-title":"Molecular Vision"},{"key":"e_1_2_13_92_2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/02713683.2013.779720","article-title":"Direct comparison of administration routes for AAV8-mediated ocular gene therapy","volume":"38","author":"Igarashi T.","year":"2013","journal-title":"Current Eye Research"},{"key":"e_1_2_13_93_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtos.2012.01.005","article-title":"Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)","volume":"10","author":"Stevenson W.","year":"2012","journal-title":"Ocular Surface"},{"key":"e_1_2_13_94_2","doi-asserted-by":"crossref","first-page":"9567","DOI":"10.1167\/iovs.11-8171","article-title":"Transduction, tropism, and biodistribution of AAV vectors in the lacrimal gland","volume":"52","author":"Rocha E. M.","year":"2011","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_13_95_2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0014-4835(02)00275-0","article-title":"Gene transfer into rabbit keratocytes using AAV and lipid-mediated plasmid DNA vectors with a lamellar flap for stromal access","volume":"76","author":"Mohan R. R.","year":"2003","journal-title":"Experimental Eye Research"},{"key":"e_1_2_13_96_2","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2011.303","article-title":"In vivo gene delivery using microvesicle-associated AAV","volume":"20","author":"Maguire C. A.","year":"2012","journal-title":"Molecular Therapy"},{"key":"e_1_2_13_97_2","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202108360","article-title":"Anti-angiogenic nanomicelles for the topical delivery of aflibercept to treat retinal neovascular disease","volume":"34","author":"Zhao X.","year":"2021","journal-title":"Advances in Materials"},{"key":"e_1_2_13_98_2","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13020258","article-title":"Assessment of in-situ gelling microemulsion systems upon temperature and dilution condition for corneal delivery of bevacizumab","volume":"13","author":"Peira E.","year":"2021","journal-title":"Pharmaceutics"},{"key":"e_1_2_13_99_2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-18002-9","article-title":"AAV vector-meditated expression of HLA-G reduces injury-induced corneal vascularization, immune cell infiltration, and fibrosis","volume":"7","author":"Hirsch M. L.","year":"2017","journal-title":"Scientific Reports"},{"key":"e_1_2_13_100_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.omtm.2020.05.014","article-title":"Ocular tolerability and immune response to corneal intrastromal AAV- gene therapy in New Zealand white rabbits","volume":"18","author":"Song L.","year":"2020","journal-title":"Molecular therapy. Methods & clinical development"},{"key":"e_1_2_13_101_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143956","article-title":"Gene delivery by subconjunctival injection of adenovirus in rats: a study of local distribution, transgene duration and safety","volume":"10","author":"Liu G.-S.","year":"2015","journal-title":"PLoS One"},{"key":"e_1_2_13_102_2","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1002\/jps.23127","article-title":"MRI study of subconjunctival and intravitreal injections","volume":"101","author":"Li S. K.","year":"2012","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"e_1_2_13_103_2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana R.","year":"2010","journal-title":"The AAPS Journal"},{"key":"e_1_2_13_104_2","article-title":"Efficient corneal gene delivery following subconjunctival administrations of AAV vectors","volume":"27","author":"Song L. J.","year":"2019","journal-title":"Molecular Therapy"},{"key":"e_1_2_13_105_2","first-page":"149","article-title":"The blood-aqueous barrier","volume":"105","author":"Bill A.","year":"1986","journal-title":"Transactions of the Ophthalmological Societies of the United Kingdom"},{"key":"e_1_2_13_106_2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.5301\/EJO.2010.6049","article-title":"Blood-retinal barrier","volume":"21","author":"Cunha-Vaz J.","year":"2011","journal-title":"European Journal of Ophthalmology"},{"key":"e_1_2_13_107_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0039-6257(90)90048-Z","article-title":"Anterior chamber associated immune deviation: the privilege of immunity in the eye","volume":"35","author":"Streilein J. W.","year":"1990","journal-title":"Survey of Ophthalmology"},{"key":"e_1_2_13_108_2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nri.2017.100","article-title":"Organ-specific protection mediated by cooperation between vascular and epithelial barriers","volume":"17","author":"Spadoni I.","year":"2017","journal-title":"Nature Reviews Immunology"},{"key":"e_1_2_13_109_2","article-title":"Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses","volume":"13","author":"Chan Y. K.","year":"2021","journal-title":"Science Translational Medicine"},{"key":"e_1_2_13_110_2","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ymthe.2020.11.029","article-title":"Clinical perspective: treating RPE65-associated retinal dystrophy","volume":"29","author":"Maguire A. M.","year":"2021","journal-title":"Molecular Therapy"},{"key":"e_1_2_13_111_2","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013392","article-title":"Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders","volume":"13","author":"Pavlou M.","year":"2021","journal-title":"EMBO Molecular Medicine"},{"key":"e_1_2_13_112_2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000099253","article-title":"Immune privilege and angiogenic privilege of the cornea","volume":"92","author":"Cursiefen C.","year":"2007","journal-title":"Chemical Immunology and Allergy"},{"key":"e_1_2_13_113_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman J.","year":"1995","journal-title":"Nature Medicine"},{"key":"e_1_2_13_114_2","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization","volume":"39","author":"Amano S.","year":"1998","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_13_115_2","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1172\/JCI20465","article-title":"VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment","volume":"113","author":"Cursiefen C.","year":"2004","journal-title":"Journal of Clinical Investigation"},{"key":"e_1_2_13_116_2","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial","volume":"19","author":"Hauswirth W. W.","year":"2008","journal-title":"Human Gene Therapy"},{"key":"e_1_2_13_117_2","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","article-title":"Age-dependent effects of RPE65 gene therapy for Leber\u2019s congenital amaurosis: a phase 1 dose-escalation trial","volume":"374","author":"Maguire A. M.","year":"2009","journal-title":"The Lancet"},{"key":"e_1_2_13_118_2","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani A. C.","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_13_119_2","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2008-07-167510","article-title":"AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells","volume":"114","author":"Mingozzi F.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_13_120_2","first-page":"1760","article-title":"Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential","volume":"14","author":"Li Q.","year":"2008","journal-title":"Molecular Vision"},{"key":"e_1_2_13_121_2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2019.05.014","article-title":"Prevalence of anti-adeno-associated virus immune responses in international cohorts of healthy donors","volume":"14","author":"Kruzik A.","year":"2019","journal-title":"Methods & Clinical Development"},{"key":"e_1_2_13_122_2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Verdera H. C.","year":"2020","journal-title":"Molecular Therapy"},{"key":"e_1_2_13_123_2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000659","article-title":"Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness","volume":"2","author":"Amado D.","year":"2010","journal-title":"Science Translational Medicine"},{"key":"e_1_2_13_124_2","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber\u2019s congenital amaurosis","volume":"358","author":"Bainbridge J. W. B.","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_13_125_2","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis","volume":"358","author":"Maguire A. M.","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_13_126_2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10456-016-9515-8","article-title":"Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes","volume":"19","author":"MacDonald D. A.","year":"2016","journal-title":"Angiogenesis"},{"key":"e_1_2_13_127_2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.omtm.2018.11.005","article-title":"AAV2\/8 anti-angiogenic gene therapy using single-chain antibodies inhibits murine choroidal neovascularization","volume":"13","author":"Hughes C. P.","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"e_1_2_13_128_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.omtm.2020.01.006","article-title":"Factors impacting efficacy of AAV-mediated CRISPR-based genome editing for treatment of choroidal neovascularization","volume":"17","author":"Chung S. H.","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"e_1_2_13_129_2","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/mt.2014.3","article-title":"Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo","volume":"22","author":"Cesana D.","year":"2014","journal-title":"Molecular Therapy"},{"key":"e_1_2_13_130_2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren R. E.","year":"2014","journal-title":"Lancet"},{"key":"e_1_2_13_131_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.omtm.2021.06.007","article-title":"Efficacious, safe, and stable inhibition of corneal neovascularization by AAV-vectored anti-VEGF therapeutics","volume":"22","author":"Su W.","year":"2021","journal-title":"Molecular Therapy. Methods & Clinical Development."},{"key":"e_1_2_13_132_2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/sj.gt.3301695","article-title":"Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy","volume":"9","author":"Lai Y. K. Y.","year":"2002","journal-title":"Gene Therapy"},{"key":"e_1_2_13_133_2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtn.2017.12.019","article-title":"Transcriptome profiling of neovascularized corneas reveals miR-204 as a multi-target biotherapy deliverable by rAAVs","volume":"10","author":"Lu Y.","year":"2018","journal-title":"Molecular Therapy - Nucleic Acids"},{"key":"e_1_2_13_134_2","doi-asserted-by":"crossref","first-page":"7989","DOI":"10.1167\/iovs.12-10658","article-title":"Inhibition of choroidal and corneal pathologic neovascularization by Plgf1-de gene transfer","volume":"53","author":"Tarallo V.","year":"2012","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_13_135_2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","article-title":"AAV-based in vivo gene therapy for neurological disorders","volume":"22","author":"Ling Q.","year":"2023","journal-title":"Nature Reviews Drug Discovery"},{"key":"e_1_2_13_136_2","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.ymthe.2017.04.003","article-title":"In utero transfer of adeno-associated viral vectors produces long-term factor IX levels in a cynomolgus macaque model","volume":"25","author":"Mattar C. N. Z.","year":"2017","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"e_1_2_13_137_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen G. N.","year":"2021","journal-title":"Nature Biotechnology"},{"key":"e_1_2_13_138_2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/jgm.1118","article-title":"The transient expression of mRNA coding for Rep protein from AAV facilitates targeted plasmid integration","volume":"10","author":"Howden S. E.","year":"2008","journal-title":"The Journal of Gene Medicine"},{"key":"e_1_2_13_139_2","article-title":"Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration","volume":"8","author":"She K.","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"e_1_2_13_140_2","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1089\/hum.2023.017","article-title":"Split AAV8 mediated ABCA4 expression for gene therapy of mouse stargardt disease (STGD1)","volume":"34","author":"Li R.","year":"2023","journal-title":"Human Gene Therapy"}],"container-title":["Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2024\/5487973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T22:44:49Z","timestamp":1732747489000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2024\/5487973"}},"subtitle":[],"editor":[{"given":"Yedi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":140,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1155\/2024\/5487973"],"URL":"https:\/\/doi.org\/10.1155\/2024\/5487973","archive":["Portico"],"relation":{},"ISSN":["2090-004X","2090-0058"],"issn-type":[{"value":"2090-004X","type":"print"},{"value":"2090-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"5487973"}}